Arovella Therapeutics Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
ALA
- Investments
-
4
- Share Price
-
$0.03
- (As of Friday Closing)
Arovella Therapeutics General Information
Description
Arovella Therapeutics Ltd is engaged in the development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer. Its invariant Natural Killer T (iNKT) cell therapy platform is being developed as a next-generation, allogeneic off-the-shelf cell therapy platform with potential applications across blood cancers, solid tumours and selected autoimmune diseases. Its product, ALA-101, is a CD19-directed CAR-iNKT cell therapy for relapsed or refractory CD19- positive blood cancers. Arovella is expanding the platform into solid tumours through ALA-105, its CLDN18.2-targeting CAR-iNKT program for gastric and pancreatic cancers, and through incorporation of IL-12-TM armouring technology designed to enhance CARiNKT cell activity and durability.
Contact Information
Website
www.arovella.comCorporate Office
- Corporate One
- 84 Hotham Street
- Preston, Victoria 3072
- Australia
Corporate Office
- Corporate One
- 84 Hotham Street
- Preston, Victoria 3072
- Australia
Arovella Therapeutics Timeline
Arovella Therapeutics Stock Performance
As of 20-Nov-2026, Arovella Therapeutics’s stock price is $0.03. Its current market cap is $36.2M with 1.21B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.03 | $0.03 | $0.03 - $0.07 | $36.2M | 1.21B | 699K |
Arovella Therapeutics Financials Summary
As of 30-Sep-2026, Arovella Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 30,520 | 38,251 | 69,960 | 94,643 |
| Revenue | 88 | 11 | ||
| EBITDA | (5,148) | (5,041) | (5,789) | |
| Net Income | (4,685) | (4,859) | (5,732) | |
| Total Assets | 10,329 | 14,109 | 8,879 | |
| Total Debt | 0 | 0 | 0 |
Arovella Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Arovella Therapeutics Comparisons
Industry
Financing
Details
Arovella Therapeutics Competitors (2)
One of Arovella Therapeutics’s 2 competitors is Kira Biotech, a Venture Capital-Backed company based in Toowong, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kira Biotech | Venture Capital-Backed | Toowong, Australia | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
Arovella Therapeutics Patents
Arovella Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202103100-D0 | Mitigating the off-target pharmacology of anagrelide in the treatment of thrombocytosis in various diseases | Inactive | 05-Mar-2021 | ||
| AU-2016904449-A0 | Mucosal active agent delivery | Inactive | 31-Oct-2016 | ||
| AU-2017351744-A1 | Mucosal active agent delivery | Inactive | 31-Oct-2016 | ||
| CA-3041112-A1 | Mucosal active agent delivery | Inactive | 31-Oct-2016 | ||
| EP-3532068-A1 | Mucosal active agent delivery | Inactive | 31-Oct-2016 | A61K47/22 |
Arovella Therapeutics Signals
Arovella Therapeutics Investments & Acquisitions (4)
Arovella Therapeutics’s most recent deal was a Corporate Asset Purchase with Aluztra Bio (Global Intellectual Property for Anagrelide). The deal was made on 01-Jan-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aluztra Bio (Global Intellectual Property for Anagrelide) | 01-Jan-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Novadel Pharma | 13-Aug-2013 | Merger/Acquisition | Drug Delivery | ||
| Westcoast Surgical & Medical Supplies | 30-May-2006 | Merger/Acquisition | Distributors (Healthcare) | ||
| Medical Industries Australia | 22-Sep-2003 | Merger/Acquisition | Distributors (Healthcare) |
Arovella Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Arovella Therapeutics Exits (2)
Arovella Therapeutics’s most recent exit was on 30-May-2006 from Westcoast Surgical & Medical Supplies. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Westcoast Surgical & Medical Supplies | 30-May-2006 | Completed |
|
||
| Medical Industries Australia | 22-Sep-2003 | Merger/Acquisition | Completed |
Arovella Therapeutics FAQs
-
When was Arovella Therapeutics founded?
Arovella Therapeutics was founded in 1999.
-
Where is Arovella Therapeutics headquartered?
Arovella Therapeutics is headquartered in Preston, Australia.
-
What is the size of Arovella Therapeutics?
Arovella Therapeutics has 8 total employees.
-
What industry is Arovella Therapeutics in?
Arovella Therapeutics’s primary industry is Drug Discovery.
-
Is Arovella Therapeutics a private or public company?
Arovella Therapeutics is a Public company.
-
What is Arovella Therapeutics’s stock symbol?
The ticker symbol for Arovella Therapeutics is ALA.
-
What is the current stock price of Arovella Therapeutics?
As of 20-Nov-2026 the stock price of Arovella Therapeutics is $0.03.
-
What is the current market cap of Arovella Therapeutics?
The current market capitalization of Arovella Therapeutics is $36.2M.
-
Who are Arovella Therapeutics’s competitors?
Kira Biotech and Gilead are competitors of Arovella Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process